Search

Your search keyword '"Glisoxepid"' showing total 10 results
Start Over "Glisoxepid" Topic azepines
10 results on '"Glisoxepid"'

1. [Clinical experience with the blood sugar reducing sulfonamide derivative glisoxepide].

Author

Petzoldt R, Riedesel G, Ramrath M, Grabs V, Haupt E, Schwedes U, Ewald W, Beyer J, and Schöffling K

Subjects
Azepines adverse effects, Carbutamide therapeutic use, Clinical Trials as Topic, Drug Evaluation, Female, Glycosuria chemically induced, Humans, Hypoglycemic Agents adverse effects, Kidney metabolism, Male, Middle Aged, Oxazoles adverse effects, Sulfonylurea Compounds adverse effects, Time Factors, Tolbutamide therapeutic use, Azepines therapeutic use, Diabetes Mellitus drug therapy, Hypoglycemic Agents therapeutic use, Oxazoles therapeutic use, Sulfonylurea Compounds therapeutic use
Published
1974

2. [The toxicology of glisoxepide, a new oral antidiabetic. Results of animal studies].

Author

Tettenborn D

Subjects
Abnormalities, Drug-Induced, Administration, Oral, Animals, Blood Glucose, Body Weight, Cats, Depression, Chemical, Dogs, Drug Evaluation, Preclinical, Female, Fertility drug effects, Glucose Tolerance Test, Hypoglycemia chemically induced, Hypoglycemic Agents pharmacology, Injections, Intravenous, Lethal Dose 50, Mice, Neoplasms chemically induced, Pregnancy, Rabbits, Rats, Seizures chemically induced, Sulfonylurea Compounds pharmacology, Time Factors, Azepines toxicity, Hypoglycemic Agents toxicity, Oxazoles toxicity, Sulfonylurea Compounds toxicity
Published
1974

3. [Multicentric clinical proof of a new oral antidiabetic glisoxepide (BS 4231). 3. Results of tolerance tests].

Author

Kiesselbach NH, Blumenbach L, and Lehnert J

Subjects
Alanine Transaminase blood, Aspartate Aminotransferases blood, Azepines adverse effects, Blood Glucose, Chemical and Drug Induced Liver Injury, Clinical Trials as Topic, Drug Evaluation, Drug Hypersensitivity, Gastrointestinal Diseases chemically induced, Humans, Hyperlipidemias chemically induced, Hypoglycemic Agents adverse effects, Kidney Diseases chemically induced, Oxazoles adverse effects, Paresthesia chemically induced, Photosensitivity Disorders chemically induced, Sulfonylurea Compounds adverse effects, Time Factors, Azepines therapeutic use, Diabetes Mellitus drug therapy, Hypoglycemic Agents therapeutic use, Oxazoles therapeutic use, Sulfonylurea Compounds therapeutic use
Published
1974

4. [Pharmacokinetics and metabolite spectrum of glisoxepide in humans].

Author

Speck U, Mützel W, Kolb KH, Acksteiner B, and Schulze PE

Subjects
Adult, Aged, Carbon Dioxide metabolism, Carbon Radioisotopes, Chromatography, Diabetes Mellitus metabolism, Drug Evaluation, Feces analysis, Female, Half-Life, Humans, Kidney metabolism, Kinetics, Male, Middle Aged, Spectrophotometry, Ultraviolet, Sulfur Radioisotopes, Tritium, Azepines metabolism, Hypoglycemic Agents metabolism, Oxazoles metabolism, Sulfonylurea Compounds metabolism
Published
1974

5. [Pharmacokinetics of radioactively labeled glisoxepide in the animal].

Author

Kolb KH, Schulze PE, Speck U, and Acksteiner B

Subjects
Animals, Bile metabolism, Carbon Radioisotopes, Computers, Dogs, Drug Evaluation, Preclinical, Feces analysis, Female, Half-Life, Haplorhini, Kidney metabolism, Kinetics, Male, Pancreas metabolism, Papio, Rabbits, Rats, Species Specificity, Sulfur Radioisotopes, Time Factors, Tritium, Azepines metabolism, Hypoglycemic Agents metabolism, Oxazoles metabolism, Sulfonylurea Compounds metabolism
Published
1974

6. [Multicentric clinical proof of a new oral antidiabetic glisoxepide (BS 4231). 1. Establishment of proof and methods].

Author

Lehnert J, Kiesselbach NH, and Blumenbach L

Subjects
Alkaline Phosphatase blood, Blood Pressure, Clinical Trials as Topic, Drug Evaluation, Drug Tolerance, Electrocardiography, Humans, Methods, Research Design, Statistics as Topic, Time Factors, Azepines therapeutic use, Diabetes Mellitus drug therapy, Hypoglycemic Agents therapeutic use, Oxazoles therapeutic use, Sulfonylurea Compounds therapeutic use
Published
1974

7. [Behavior of serum insulin under the influence of glisoxepide with and without butylbiguanide].

Author

Birk W and Petrides P

Subjects
Aged, Antigens analysis, Blood Glucose analysis, Depression, Chemical, Drug Evaluation, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents pharmacology, Insulin analysis, Male, Middle Aged, Sulfonylurea Compounds pharmacology, Time Factors, Azepines therapeutic use, Biguanides therapeutic use, Diabetes Mellitus drug therapy, Hypoglycemic Agents therapeutic use, Insulin blood, Oxazoles therapeutic use, Sulfonylurea Compounds therapeutic use
Published
1974

8. [Multicentric clinical proof of a new oral antidiabetic glisoxepide (BS 4231). II. Proof of activity in the management of adult onset diabetes].

Author

Blumenbach L, Kiesselbach NH, and Lehnert J

Subjects
Adult, Aged, Blood Glucose, Blood Pressure, Body Weight, Clinical Trials as Topic, Drug Evaluation, Female, Humans, Lipids blood, Male, Middle Aged, Statistics as Topic, Time Factors, Azepines therapeutic use, Diabetes Mellitus drug therapy, Hypoglycemic Agents therapeutic use, Oxazoles therapeutic use, Sulfonylurea Compounds therapeutic use
Published
1974

9. Pharmacological study of a new hypoglycaemic sulphonamide: glisoxepid (RP 22410)

Author

Ribes G, Agot H, Loubatières Al, Alric R, and Mariani Mm

Subjects
Drug, Blood Glucose, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, media_common.quotation_subject, Tolbutamide, Administration, Oral, Pharmacology, In Vitro Techniques, Neogenesis, Islets of Langerhans, Mice, Dogs, Pancreatectomy, Oral administration, Internal medicine, Insulin Secretion, Internal Medicine, medicine, Animals, Insulin, Oxazoles, Pancreas, media_common, geography, geography.geographical_feature_category, biology, business.industry, Azepines, biology.organism_classification, Islet, In vitro, Stimulation, Chemical, Rats, Perfusion, medicine.anatomical_structure, Endocrinology, Sulfonylurea Compounds, Injections, Intravenous, business, medicine.drug
Abstract

Glisoxepid or RP 22410 is a new very active hypoglycaemic sulphonylurea. In the normal conscious dog, RP 22410 administered intravenously was 81 or 131 times more active than tolbutamide, depending on whether the dose is expressed in grams or in moles. The hypoglycaemic effect did not occur in the totally pancreatectomized dog. — RP 22410 stimulated insulin secretion.In vivo in the anaesthetized or conscious dog, the action of the drug (whether it be administered intravenously or orally) resulted in a rapid and considerable increase of the amount of insulin secreted by the pancreas. This action lasted several hours.In vitro the direct action of the product on the pancreas was demonstrated on the isolated and perfused rat pancreas, even at very low concentrations. — In the mouse, prolonged oral administration of RP 22410 stimulated neogenesis of the islets of Langerhans and of the beta cells. It therefore possesses betacytotrophic action.

Published
1972

10. Insulinotrophic Drugs: Effect on Intestinal Absorption of Sugar

Author

A Ghareeb, N Wahba, M Botros, Kh Ghoneim, and R Selim

Subjects
medicine.medical_specialty, Tolbutamide, Endocrinology, Diabetes and Metabolism, Intestinal absorption, Glibenclamide, chemistry.chemical_compound, Animal science, Ileum, Glyburide, Intestine, Small, Internal Medicine, medicine, Animals, Hypoglycemic Agents, Sugar, Oxazoles, Sulfonamides, Chemistry, Galactose, Biological Transport, Azepines, Rats, Surgery, Perfusion, Pyrimidines, Sulfonylurea Compounds, Intestinal Absorption, Continuous perfusion, Glisoxepid, Ethers, medicine.drug
Abstract

The effect of some insulinotrophic drugs on the transport of sugar was investigated in fasted, narcotized rats by continuous perfusion of cannulated long intestinal loops with galactose solution (18 mM.) circulated by air lift. Three consecutive perfusions (fifty minutes each) were performed in each rat, the drug being given in the second perfusion only. The rate of galactose disappearance was expressed as per cent of that in the first perfusion in the same rat. Tolbutamide (50 mg./l kg. weight), glycodiazine (50 mg./l kg. weight), glisoxepid (BAY 4231, 2 mg./l kg. weight) and glibenclamide (0.25 mg./l kg. weight) were found to increase the rate of galactose disappearance in the second perfusion by 21 per cent, 5 per cent, 12 per cent and 25 per cent, respectively, and in the third perfusion by 21 per cent, 26 per cent, 32 per cent and 21 per cent, respectively, as compared to the rate in the corresponding perfusion of a control group. This increase was significant (P values < 0.05) with all drugs in the second and third perfusions with the exception of glisoxepid in the second perfusion. These results are discussed in relation to the action of insulin and the effect of diabetes on intestinal absorption of sugars.

Published
1974
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results